Open AccessNon-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Author(s) -
Wassim Abida,
David Campbell,
Akash Patnaik,
Jeremy Shapiro,
Brieuc Sautois,
Nicholas J. Vogelzang,
Éric Voog,
Alan H. Bryce,
Ray McDermott,
Francesco Ricci,
Julie Rowe,
Jingsong Zhang,
Josep María Piulats,
Karim Fizazi,
Axel S. Merseburger,
Celestia S. Higano,
Laurence E. Krieger,
Charles J. Ryan,
Felix Y. Feng,
Andrew Simmons,
Andrea Loehr,
Darrin Despain,
Melanie Dowson,
Foad Green,
Simon P. Watkins,
Tony Golsorkhi,
Simon Chowdhury
Publication year - 2020
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-20-0394
Subject(s) - chek2 , prostate cancer , medicine , olaparib , parp inhibitor , palb2 , dna repair , oncology , cancer , synthetic lethality , cancer research , germline mutation , biology , mutation , poly adp ribose polymerase , gene , genetics , polymerase
Genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate cancer (mCRPC). To test this hypothesis, the phase II TRITON2 study of rucaparib included patients with mCRPC and deleterious non- BRCA DDR gene alterations.